Intellia Therapeutics/$NTLA
Intellia shares rise after the FDA accepted lonvo-z’s BLA for priority review, supported by positive Phase 3 HAELO data showing an 87% reduction in hereditary angioedema attacks after one dose.
1 hour agoLightyear AI
1D1W1MYTD1Y5YMAX
Capital at risk
About Intellia Therapeutics
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
- Ticker
- $NTLA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 377
- Headquarters
- Cambridge, United States
- Website
- www.intelliatx.com
NTLA Metrics
BasicAdvanced
$1.6B
-
-$3.34
1.79
-
Price and volume
Market cap
$1.6B
Beta
1.79
52-week high
$28.25
52-week low
$7.95
Average daily volume
3.4M
Financial strength
Current ratio
6.648
Quick ratio
5.606
Long term debt to equity
0.069
Total debt to equity
0.101
Profitability
EBITDA (TTM)
-414.4
Gross margin (TTM)
-374.44%
Net profit margin (TTM)
-672.16%
Operating margin (TTM)
-711.66%
Revenue per employee (TTM)
$160,000
Management effectiveness
Return on assets (TTM)
-30.14%
Return on equity (TTM)
-55.44%
Valuation
Price to revenue (TTM)
23.093
Price to book
2.21
Price to tangible book (TTM)
2.21
Price to free cash flow (TTM)
-3.941
Free cash flow yield (TTM)
-25.37%
Free cash flow per share (TTM)
-2.916
Growth
Revenue change (TTM)
12.58%
Earnings per share change (TTM)
-28.59%
3-year revenue growth (CAGR)
3.91%
10-year revenue growth (CAGR)
20.31%
3-year earnings per share growth (CAGR)
-14.98%
10-year earnings per share growth (CAGR)
-3.01%
What the Analysts think about NTLA
Analyst ratings (Buy, Hold, Sell) for Intellia Therapeutics stock.
Analyst projections of the future price of Intellia Therapeutics stock.
Bulls say / Bears say
Lonvo-z produced strong Phase 3 HAELO results. A single infusion cut mean monthly hereditary angioedema attacks by 87% versus placebo, and 62% of treated patients were both attack-free and free of HAE therapy over six months, compared with 11% on placebo. (GlobeNewswire, Markets Insider)
The FDA has accepted lonvo-z’s BLA for Priority Review and set a 10 March 2027 decision date, with no advisory committee currently planned. If approved, it would be the first in-vivo CRISPR therapy and the only one-time HAE treatment, creating a clear near-term catalyst and potential first-mover advantage. (Investing News Network, Markets Insider)
Intellia ended June with $628.4 million in cash, cash equivalents and marketable securities, which management expects to fund operations at least into 2028 without counting lonvo-z revenue. A new OrbiMed facility can add up to $400 million, helping fund the planned launch and ongoing ATTR trials without an immediate share issue. (GlobeNewswire, BioSpace)
Nex-z’s ATTR programme still carries a safety overhang. Intellia found an HLA allele linked to liver-enzyme elevations, leading to HLA typing and tighter monitoring after the Phase 3 trials resumed. (The Motley Fool, GlobeNewswire)
Intellia remains loss-making and has already relied on financing to fund its next phase. The April share offering raised about $195 million, while the Q2 net loss was $106.6 million; continued spending could mean further dilution or borrowing before products generate revenue. (GlobeNewswire, TradingKey)
Lonvo-z still faces clinical and regulatory uncertainty despite the BLA acceptance. The pivotal HAELO trial involved only 80 patients and reported its main comparison over six months, while FDA acceptance and Priority Review do not guarantee approval or prove long-term durability. (Markets Insider, GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 17 Sept 2026.
NTLA Financial Performance
Revenues and expenses
NTLA Earnings Performance
Company profitability
Upcoming events
No upcoming events
NTLA News
AllArticlesVideos
Funds containing NTLA
AllUSDGBPEUR
Fund name | Fund size | $NTLA weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.11% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.11% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.05% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.02% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.